McGill University
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1821-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mcgill.ca
Clinical Trials
241
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (215 trials with phase data)• Click on a phase to view related trials
Examining the Acceptability and Effectiveness of a Self-Directed, Web-Based Resource for Stress and Coping in University: Randomized Controlled Trial
- Conditions
- StressCopingCoping BehaviorWell-Being (Psychological Flourishing)Digital Intervention
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- McGill University
- Target Recruit Count
- 242
- Registration Number
- NCT07086001
- Locations
- 🇨🇦
McGill University, Montreal, Quebec, Canada
Enhancing Preschool Children's Attention and Behaviour: Parent-Focused Program
- Conditions
- Maternal DepressionAttention ProblemsSelf-Regulation, EmotionParental StressChild Mental DisorderChild DevelopmentBehaviour Problems
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- McGill University
- Target Recruit Count
- 60
- Registration Number
- NCT07083037
- Locations
- 🇨🇦
University of Manitoba - Department of Psychology, Winnipeg, Manitoba, Canada
🇨🇦McGill University - Department of Education and Counselling Psychology, Montreal, Quebec, Canada
Feasibility and Acceptability of an Evidence-Informed Virtual Intervention to Reduce Perceptions of Injustice Following Work Injury
- Conditions
- MSK Conditions
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- McGill University
- Target Recruit Count
- 75
- Registration Number
- NCT07072702
- Locations
- 🇨🇦
McGill University, Montreal, Quebec, Canada
Error Augmentation for Upper Limb Rehabilitation in Stroke Survivors
- Conditions
- Stroke
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- McGill University
- Target Recruit Count
- 28
- Registration Number
- NCT07039006
- Locations
- 🇨🇦
Jewish Rehabilitation Hospital, Montreal, Quebec, Canada
Music as an Adjunct to Ketamine Therapy for Chronic Pain
- Conditions
- Chronic PainChronic Noncancer Pain
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- McGill University
- Target Recruit Count
- 25
- Registration Number
- NCT06994559
- Locations
- 🇨🇦
Montreal General Hospital, Montreal, Quebec, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 47
- Next
News
Epitopea's CryptoMap Platform Identifies Novel Immunotherapy Targets in Melanoma and NSCLC
Epitopea's CryptoMap platform identified 589 non-redundant tumor antigens in cutaneous melanoma and NSCLC, with only 1% derived from mutated sequences.
Novel Nucleus Pulposus Allograft Shows Promise for Chronic Back Pain Treatment
Clinical trials of VIA Disc NP, a minimally invasive treatment using donor nucleus pulposus tissue, demonstrated significant reduction in chronic back pain from 7.1 to 3.8 on a 10-point scale over 12 months.
Lecanemab's Effectiveness for Alzheimer's May Be Significantly Lower in Female Patients, Study Suggests
• Recent analysis of lecanemab (Leqembi) clinical trial data reveals a 31% difference in drug effectiveness between male and female Alzheimer's patients, with men showing a 43% slowing of cognitive decline compared to just 12% in women. • Researchers from McGill University conducted 10,000 simulated trials based on Phase 3 CLARITY AD data, finding the gender disparity occurred randomly in only 12 simulations, suggesting the difference is statistically meaningful. • The findings have significant implications for clinical practice as two-thirds of Alzheimer's patients are female, highlighting the urgent need for sex-specific considerations in both drug development and treatment decisions.
Study Reveals 16% of Phase 2 Cancer Trial Patients Receive Eventually FDA-Approved Drugs
A comprehensive analysis of 2,730 phase 2 cancer trials shows that one in six patients receives treatments that ultimately gain FDA approval, providing important insights for clinical trial recruitment.